Kynam Capital Management, LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001907884
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q4 2023 · 24 positions · Total reported value $902.61M · Top-10 concentration 78.4% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 48.8% · 4 new · 7 cut · 9 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +14.0% · vs SPY -0.8% · Prev Value $1.55B — last quarter positions weighted by this quarter price moves · ranking
In its Q4 2023 13F filing, Kynam Capital Management, LP disclosed 24 equity positions with a combined reported value of $902.61M. The filing implies a focused portfolio: its ten largest positions account for 78.4% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q4 2023 were NTRA ($150.34M), SNDX ($122.31M), CLDX ($119.21M). By sector, the heaviest allocations are Health Care 84.1%, Other 15.9%. Versus the prior quarter, allocation shifted toward Other (+7.2pp) and away from Health Care (-7.2pp).
Versus the prior quarter, Kynam Capital Management, LP opened 4 new positions, trimmed 7 and fully exited 9, a turnover rate of 48.8% of positions. The portfolio's overlap with the prior quarter was 62% of names.
The largest new positions opened in Q4 2023 were IMGN ($42.18M), MOR ($41.92M), CORT ($19.03M).
Of the 9 positions fully exited versus the prior quarter, the largest were TSHA ($10.37M), IMVT ($3.84M), OLMA ($2.90M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q4 2023)
- IMGN IMMUNOGEN INC · $42.18M
- MOR MORPHOSYS AG · $41.92M
- CORT CORCEPT THERAPEUTICS INC · $19.03M
- TYRA TYRA BIOSCIENCES INCORPORATED · $4.71M
Fully Exited (vs previous quarter)
- TSHA TAYSHA GENE THERAPIES IN · prev qtr: $10.37M
- IMVT IMMUNOVANT INC · prev qtr: $3.84M
- OLMA OLEMA PHARMACEUTICALS INC · prev qtr: $2.90M
- PBYI PUMA BIOTECHNOLOGY INC · prev qtr: $1.25M
- CNTB CONNECT BIOPHARMA HLDGS LTD · prev qtr: $434.00K
- GOSS GOSSAMER BIO INC · prev qtr: $208.20K
- NLTX NEOLEUKIN THERAPEUTICS INC · prev qtr: $94.95K
- CBIO CRESCENT BIOPHARMA INC. · prev qtr: $43.44K
Insider Transactions (Form 4)
Latest Kynam Capital Management, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Kynam Capital Management, LP files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 32 positions worth $1.81B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- SEC registration: 801-126187 (status: Approved), registered 2022-07-22
- Regulatory AUM (Form ADV): $2.41B as of 2026-04-10
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 1 private funds, of which 1 hedge funds
Portfolio Structure
- 32 positions · $1.81B reported value (Q2 2026)
- Top 10 holdings = 72.7% of reported value
- Largest position: CLDX (CELLDEX THERAPEUTICS INC NEW) at 10.9%
- Average position size: $56.54M
Sector Tilt
- Health Care 100.0%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 4 new, 12 added, 7 reduced, 9 exited
- 9 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
2.40M | $150.34M | 16.66% | Reduce | |
| 2 |
|
5.66M | $122.31M | 13.55% | Add | |
| 3 |
|
3.01M | $119.21M | 13.21% | Reduce | |
| 4 |
|
1.00M | $62.95M | 6.97% | Reduce | |
| 5 |
|
3.65M | $56.14M | 6.22% | Add | |
| 6 |
|
2.00M | $45.97M | 5.09% | Add | |
| 7 |
|
1.42M | $42.18M | 4.67% | New | |
| 8 |
|
4.23M | $41.92M | 4.64% | New | |
| 9 |
|
5.85M | $34.43M | 3.81% | Add | |
| 10 |
|
2.70M | $32.46M | 3.60% | Add | |
| 11 |
|
4.60M | $27.55M | 3.05% | Add | |
| 12 |
|
5.95M | $25.42M | 2.82% | Hold | |
| 13 |
|
1.51M | $21.17M | 2.35% | Add | |
| 14 |
|
3.93M | $19.86M | 2.20% | Hold | |
| 15 |
|
585.90K | $19.03M | 2.11% | New | |
| 16 |
|
2.00M | $17.98M | 1.99% | Add | |
| 17 |
|
607.91K | $13.24M | 1.47% | Reduce | |
| 18 |
|
12.02M | $10.46M | 1.16% | Hold | |
| 19 |
|
1.20M | $8.95M | 0.99% | Hold | |
| 20 |
|
2.00M | $8.59M | 0.95% | Add | |
| 21 |
|
8.69M | $8.09M | 0.90% | Add | |
| 22 |
|
1.07M | $6.12M | 0.68% | Hold | |
| 23 |
|
340.19K | $4.71M | 0.52% | New | |
| 24 |
|
442.70K | $3.52M | 0.39% | Reduce | |
FAQ
What did Kynam Capital Management, LP buy in 2023-Q4?
In its 2023-Q4 13F filing, Kynam Capital Management, LP reported 24 equity positions worth $902.61M in aggregate; its largest disclosed positions were NTRA ($150.34M), SNDX ($122.31M), CLDX ($119.21M).
How large is Kynam Capital Management, LP's portfolio?
Kynam Capital Management, LP reported $902.61M of long equity holdings across 24 positions as of 2023-Q4. Top-10 holdings account for 78.4% of reported value.
What is Kynam Capital Management, LP's investment style?
HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.